COVID-19 advice hub

COVID-19 advice hub

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 11 March 2020, the rapid circulation of SARS-CoV-2 has been classified as a pandemic by the World Health Organization.

This page is collates relevant guidance from NHS England, Public Health England, the UK Government, and professional bodies across the UK and beyond to support services with both the design and delivery of their pandemic response.

Jump to the following areas based on your needs:

Prevention

Investigation

Service organisation and resourcing

    1. freeing up maximum possible inpatient and critical care capacity
    2. preparing, and responding to, large numbers of inpatients requiring respiratory support
    3. supporting staff, and maximising staff availability
    4. supporting newly announced wider population measures
    5. stress-testing operational readiness
    6. removing routine burdens
    1. Phase 1: COVID-19 case identification and immediate response
    2. Phase 2: COVID-19 coordination services
    3. Minimum pathway accessories required, including for diagnostics, case transport, and infection prevention and control
    4. Managing illness during self-isolation based on symptom severity (‘disposition’).

NHS England


Royal College of Anaesthetists, Association of Anaesthetists, Faculty of Intensive Care Medicine, Intensive Care Society, and UK Clinical Pharmacy Association


Clinical management of acute COVID-19-related illness

Acute care

COVID-19 rapid NICE guidelines:

National Institute for Health and Care Excellence



Faculty of Intensive Care Medicine


Resuscitation Council UK


Specific patient groups and conditions

Adrenal/pituitary insufficiency


Asthma


Cancer

Chronic myeloid leukaemia


Chronic obstructive pulmonary disease


Coagulopathy


Congenital heart disease


Diabetes


Fragility fractures


Gastroenterology


Haematology


Hepatology


HIV


Hypertension

Receiving angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy

The current international consensus is that there is no good evidence that stopping ACEis or ARBs will prevent or alleviate COVID-19.


Immune thrombocytopenic purpura


Inflammatory bowel disease (including Crohn’s disease and ulcerative colitis)


Interstitial lung disease


Lung cancer and mesothelioma


Multiple sclerosis


Obstructive sleep apnoea


Ophthalmology


Paediatrics


Psoriasis


Pregnancy


Rheumatological conditions


Sickle cell disease and thalassaemia


Surgery


Transfusion


Transplantation


Trauma and orthopaedics


Patients taking warfarin


Equipment standards


Pharmacy

Other areas

Advising the public

Specialised Medicine  COVID-19 news